As reported in The Lancet by Choueiri et al, the phase III TiNivo-2 trial reported results of the immune checkpoint inhibitor rechallenge with nivolumab plus tivozanib vs tivozanib alone in patients with metastatic renal cell carcinoma following immune checkpoint inhibitor treatment.
Deintensified treatment involving a lower radiation dose and immunotherapy in place of chemotherapy may not perform as well as a more rigorous chemoradiation treatment approach in patients with early-stage human papillomavirus (HPV)-associated oropharyngeal cancer, according to new findings presented by Yom et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA03) and simultaneously published in the International Journal of Radiation Oncology • Biology • Physics.
The American Cancer Society (ACS) released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States. The new report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately 517,900 breast cancer deaths. However, not all women have benefited from this progress, notably American Indian and Alaska Native (AIAN) women, whose rates have remained unchanged over the past 3 decades. Also concerning is the continued upward trend in breast cancer incidence, rising by 1% annually during 2012–2021, with the steepest increase in women younger than 50 years (1.4% per year) and Asian American/Pacific Islander (AAPI) women of any age (2.5%–2.7% per year). These findings were reported by Giaquinto et al in CA: A Cancer Journal for Clinicians.
Two types of contemporary radiation therapy—proton-beam therapy or intensity-modulated radiation therapy—may provide comparable rates of tumor control with no differences in patient-reported quality of life among patients with low- and intermediate-risk prostate cancer, according to new findings presented by Efstathiou et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA01) and simultaneously published in the International Journal of Radiation Oncology • Biology • Physics.
Adding the immune checkpoint inhibitor durvalumab, with or without the monoclonal antibody oleclumab, to neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) significantly improved pathologic complete response rates in patients with high-risk hormone receptor (HR)-positive breast cancer, according to data presented at the European Society for Medical Oncology (ESMO) Congress 2024.
The National Comprehensive Cancer Network (NCCN) has always prided itself on its commitment to evidence-based, expert consensus–driven recommendations for cancer care, with a special focus on breaking down the barriers that contribute to disparities in outcomes across all patients with cancer. With ...
Total neoadjuvant therapy (TNT) followed by rectal surgery is the standard of care in proficient mismatch repair (pMMR) locally advanced rectal cancer, but studies are finding that patients with clinical complete response may often avoid surgery and be followed “nonoperatively.” In the first...
Vincent T. DeVita, MD George P. Canellos, MD Medical oncology had a turbulent beginning, as we explained in part 1 of this commentary published in the September 25, 2024, issue of The ASCO Post. And although no other specialty we know of struggled as much, with perseverance and time, it...
The combination of the EGFR-MET bispecific antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib continues to demonstrate superior efficacy compared with the kinase inhibitor osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...
As reported in Journal of Clinical Oncology by Gyurkocza et al, the phase III SIERRA trial has shown higher rates of durable complete remissions with the anti-CD45 radioconjugate iodine-131–apamistamab vs conventional care followed by allogeneic hematopoietic cell transplantation (allo-HCT) in...
When we add pembrolizumab, the risk of death is reduced by 33%, and that is really remarkable for this tumor [cervical cancer], which is among the worst of the gynecologic malignancies. — Domenica Lorusso, MD, PhD Tweet this quote In the phase III...
As reported in the Journal of Clinical Oncology by González-Martín et al, a phase III trial (ENGOT-OV41/GEICO 69-O/ANITA) has shown no progression-free survival benefit with the addition of atezolizumab to a carboplatin doublet and maintenance niraparib in patients with recurrent ovarian cancer...